Related to Facet Biotech Steps Up to Help Trubion Advance Early-Stage Anticancer Agent with a $20M Fee

• A SPA for PMTs
  Researchers propose a SPA strategy that can be successfully implemented to identify novel and specific inhibitors of PMTs.
  
• Leveraging Synthetic Lethality for Cancer Therapeutics
  Researchers investigate a class of therapeutics that could short-circuit cancer cells at the molecular level.
  
• Oncogene Addiction: Real or Not?
  Emerging documentation is starting to address that question and increase understanding of process.
  
• End-Running Cancer Resistance to Targeted Therapies
  Overcoming resistance may require an assault on multiple fronts.
  
• A Cyber War on Cancer
  New strategies are hoping to put an end to the war that Richard Nixon declared four decades ago.
  
• Chemotherapy for the 21st Century
  After a century of using body surface area, oncologists are warming to maximum-tolerated exposure for determining cancer drug dosages.
  
• Getting Cancer Immunotherapeutics Approved
  It’s not just the FDA standing in the way.
  
• 15 Breast Cancer Drugs in the Pipeline Right Now
  Which candidates are on their way from the lab to the medicine chests of thousands?
  
• Genome Testing Reduces Overtreatment
  Study after study has shown that molecular diagnostics can help oncologists more effectively treat patients.
  
• 10 Predictions That Will Transform Healthcare
  Peer into GEN's crystal ball for a glimpse of what's to come.
  
• DNA Methylation Rules: Studying Epigenetics with New Tools
  The tools to unravel the epigenetic control mechanisms that influence how cells control access of transcriptional proteins to DNA are just beginning to emerge.
  
• Women and Smoking
  Looking for a reason to quit, ladies? Look no further.
  
• Performing “Informative Clinical Trials” in Mice
  Patient-derived tumor xenografts: better than cancer cell lines for preclinical testing in animal models?
  
• Cancer Model Database Emerges from WOMB
  Oncology researchers wishing for a tool to help them find available models and services may have had their prayers answered.
  
• Literature Review: Which Drug Combination Will Unlock Triple-Negative Breast Cancer?
  Researchers describe a strategy for treating TNBC that combines noncompetitive antibodies to achieve degradation of EGFR and tumor inhibition.
  
• Detecting Acquired Drug Resistance in Cancer
  New methods allow noninvasive analysis in blood plasma.
  
• The Tumor Microenvironment as a Drug Target: Chasing Slippery Targets
  This first part of a two-part series discusses how researchers are looking at ways to attack tumors by targeting the cellular frameworks that keep them alive.
  
• The Tumor Microenvironment as a Drug Target, Part II
  In the search for new targets, cancer researchers are taking a closer look at the cellular support networks that allow tumors to survive.
  
• Literature Review: A Step Closer to Personalized Medicine
  Researchers use patient-specific cell lines derived in mice to personalize chemotherapy.
  
• Moving Genomics Closer to the Clinic
  Foundation Medicine and Memorial Sloan-Kettering Cancer Center are working to translate genomic information into personalized cancer treatment.